Hello, ladies and gentlemen. Thank you for standing by for ZEPP Health Corporation's Fourth Quarter and Full Year 2021 Earnings Conference Call. At this time, all participants are in listen-only mode. Today's conference call is being recorded. I will now turn the call over to your host, Ms. Grace Zhang, Director of Investor Relations for the Company. Please go ahead, Grace.

Hello, everyone. And welcome to ZEPP Health Corporation's Fourth Quarter and Full Year 2021 Earnings Conference Call. The company's financial and operating results were issued in our press release via News Wire Services earlier today and are posted online. You can also view the earnings press release and the slides which we will refer on this call by visiting the IR section of the company's website: www.ir.zepp.com . Participating in today's call are Mr. Wang Huang, our Chairman of the Board of Directors and Chief Executive Officer, and Mr. Leon Cheng Deng, our Chief Financial Officer. The company's management will begin with prepared remarks and the call will conclude with a Q&A session. Before we continue, please note that today's discussion will contain forward-looking statements under the Safe Harbor Provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties. As such, the company's actual results may be materially different from the views expressed today. Further information regarding this and other risks and uncertainties is included in the company's Annual Report on Form 20-F for the fiscal year ended December 31, 2020, and other filings as filed with U.S. Securities and Exchange Commission. The company does not assume any obligation to update any forward-looking statements, except as required under [Indiscernible] law. Please also note that Zepp's earnings press release and this conference call include discussions of unaudited GAAP financial information, as well as unaudited non-GAAP financial information. Zepp's press release contains reconciliation of the unaudited non-GAAP measures to the unaudited most directly comparable GAAP marrows. I'll now turn the call over to our CEO, Mr. Huang. Please go ahead.

Hello, everyone. Thank you for joining our call. In 2021 we made a significant [Indiscernible] despite the challenging macro environment, our full-year revenue reached 612.5 billion RMB as we [Indiscernible] our coal growth strategies in this markets consumer health and fitness sector. We maintained our profitability and, at the same time, grew our self-branded products shipments by 60% during the past year in the face of worldwide ship shortages, as well as the Delta and Omicron COVID variants. In the second half of 2021, we are very proud of that, as of that first quarter of 2021, we have cumulatively shipped over to 200 million health management devices since our inception. These achievements reflect our increasing global appear and our dedication to improving our users lives through technological advancements. Let me expand on our global progress. The momentum of our overseas expansion remains robust with over 80% of our self-branded products sourced internationally. Notably, our self-branded products shipment volumes for the North American region increased by approximately 200% year-over-year. As we enter major retail sales channels including more than 1,000 offline Target stores as well as QEC. As for European markets, our shipments to Italy and France increased by more than 100% in the fourth quarter, thanks to our country's specific strategy. We are now ranked number 5 in the Adults Smartwatch Market according to the fourth quarter, 2021 IDC market data. We have been among the top 5 in the global market top for several quarters, demonstrating our enhanced product capability and flourishing branded recognition in the growing Smart Watch Industry. As we work to enlarge our global footprint, we remain steadfast in our mission to connect health with technology. To the end, we continue to develop priority technologies, including AI chips, biometric sensors, and data algorithms to improve…

Thank you, Huang. I would like to start by highlighting some of the key metrics driving that development. As Wang mentioned, our full-year 2021 revenue was 6.25 billion RMB, representing 1% in comparable revenue growth. Our self-branded products played an important role in our 2021 results. As our full-year shipments increased by 60% despite the challenges of surging COVID -19 outbreaks and the chip shortage, which impacted shipments of both our self-branded wearables and Xiaomi wearable products. Although we cannot fully predict how the supply chain issues will evolve, we're hopeful that we'll start seeing improvements in the second half of 2022. While we see net increase in unit shipments of our brands, this growth was offset by a decrease in unit shipments of Xiaomi wearable products. Xiaomi remains as our valued partner and our Mi Band still ranks number one in market share with 35.6% of the total global smart band market. At the same time, we're also excited to expand and diversify our business and build our own brand, with the goal of achieving sustainable, long-term growth. Total revenue in Q4 was RMB 1.7 billion, representing a nominal year-over-year decrease of 15.8%. Again, this decrease was mostly driven by the decrease in bad sales. In the meantime, COVID-19 and ship shortages also constrained the growth of our self-branded products. Like many other companies, we have been facing ongoing external challenges since the second half of 2021, many of which still persist today. COVID-19 not only impacted ourselves due to wide spread our offline store closures, especially during the holiday seasons, but also dampened our courier services. For example, with the January 2022 lock-down of China's Jilin and Shenzhen parts, which are critical to our global supply chain and product availability, disrupted deliveries and sales worldwide. Moreover, the global…

We will now begin the question-and-answer session. [Operator Instructions]. For the benefit of all participants on today's call, if you wish to ask your question to the company's management in Chinese, please immediately repeat your question in English. At this time, we will pause momentarily to assemble our roster. The first question is from Yalin Lou (ph) of TNA Securities. Please go ahead.

Hi management. Thank you for taking my question. And congratulations for fourth quarter. I have two questions. Firstly, about your gross margin. We know since the beginning of the year, we see semiconductor shortage driven isn't any our courage some product company's gross margin decrease affected by the chip shortage, in this quarter, about bases in-house gross margin increased year over year, I think this beyond my expectation, can you shares on view about chip shortage impact on your gross margin and any progress about your function chip, thank you.

Yes. No, thank you for the question. On the gross margin I think, the answer is to points. Number 1, we actually proactively changed our mix towards proportionately focused on the self-branded products which carriers on average twice the gross margin if we sell our Xiaomi branded products, right? So, if you look at 2020, we have the mix which is more skewed towards 70% of Xiaomi products and 30% of self-branded products. And while we end the year of 2021, we're actually hovering around half half and then the self-branded products trend will also continue to grow into 2022. So because of that change, then you get a mix improvement on the overall gross margin. Coming back to your question on the chip shortage, we have announced in the previous quarters that we did certain risk buys ahead of this situation materialize, which also has an impact on our inventory level. But as mid to short term, we didn't see too much of a material impact on the gross margin because of the risk by with it. On the function two chip, the progress is twice -- is progressing very well according to our schedule. So in this year, you will later this year that there are certain flagship products which we're going to launch as a new product introduction, which will carry the Huangshan 2 chip. And then at the same time, we're also going to license a variant of the Huangshan 2 chip to a bigger variety of Chinese watch makers through our ITO investments, because we license this also to them, and we're also going to get certain profit out of that licensing deal as well.

Okay. A follow-up question about your gross margin, [Indiscernible] your boast Xiaomi products and sales brand product to gross margin is decreased but mix is better this quarter?

So, I think Xiaomi gross margin has been a decreasing trend for the company for a few years, right? A phase you probably also read the news that Xiaomi is actually targeting a cost plus 5%, something like that, right? So Xiaomi 's gross margin is actually in the low teens, that type of number and that has decreased quarter-over-quarter by one percentage point, something like that. But our self-branded gross margin has been quite strong and hold up over the year.

Okay. And my second question is about your marketing strategy. The global environment is more uncertain this year. So what's your marketing strategy changes in this year to -- in this global environment.

So, I think the short answer to it is no, but we do see the risk of Russia and Ukraine situation, which we also mentioned in our earnings call. We have a strong market share in Russia and Ukraine, and all those neighborhood countries. And to be honest, Russia and Ukraine's revenue, if I take 2021 full year as the basis, they stand for around 4% of our total revenue, right? So that risk, we need to manage, in short to mid-terms we think we can still manage that risk. But if this war continues into our drag down for a year or two, that definitely will have an impact on our revenue per se. But we're slightly different than the other China tech company, because majority of our self-branded products are overseas sales, so China actually stands for only a small portion of our overall mix. So, to that end, apart from Russia and Ukraine, our marketing strategy in Western Europe, which is actually a strong foothold of our revenue, and also United States didn't change, and that will continue to grow.

Okay. Thank you.

Thank you.

Okay. [Operator Instructions]. The next question is from Kevin Chen of China Ren. Please go ahead.

Hello, hi. Thank you, management, for taking my question. I have two questions. Number one will be regarding your newly launched GT 3 series. I was just wondering how the sales do, and the sales condition and general feedback so far is tracking. And how is it matching up to your expectations, is it better than expected or slightly lagging behind.

Kevin. Thank you for your questions. Now, on GT3 as Wang mentioned earlier, it's actually a very successful product. And we received a lot of good reviews in China and in overseas markets for this product. So, if you compare the GT3 against our own expectations, I think you've probably also heard that we are a little bit [Indiscernible] the chip shortage and logistics challenges in Q4, I think we're not in, the month problem. We're more having a supply problem for GT3. Compare with our own internal expectation, we think we can still do much, much more. But we're actually hurt a little bit by the COVID logistic disruptions in Q4. And that also continues a little bit into Q1. But if you, ask me, if the product is a big success, I think the product is really a big success. And we, through the launch of the GT3, we also see that we have the room to improve our ASP further not only in China, but also in overseas market. And that will also, in a longer run, help us to lift our gross margin of the company.

Right. Thank you. Just a quick follow-up. I think previously, the Chairman just mentioned that the GT3 series is being under review for China's NMPA, just for -- I guess this is for qualification for more medical application kind of use. I was just wondering, do we have an expectation of approximate timeline of how this review might turn out, and once we obtained this kind of approval with this enable our new business opportunities in the GT Series?

Yes, for sure. I think what we also mentioned, that we're not only doing it for the Chinese market, we're also doing it for the European market and also for U.S., right. So we're actually doing the certification at multiple geographies at the same time. So that -- it's related to the blood pressure movement, which you have measure using our GT 3 watch, your blood pressure, which we think is actually a very unique and elegant solution compared with our competitors, right. So, yes, the Chinese review, I think it's going to be much shorter timeline because there's going to for example, either it's going to be a software and algorithms certification. So we expect that approval should be able to obtain by somewhere in the course of this year. And then the CE and FDA review might take a little bit longer, but should not be too much longer. And then whilst we get those certifications, for sure that will give us [Indiscernible] offering new services, and also a new unique selling point versus the peers.

Okay. Got it. That's good to hear. My second question is regarding the European market as we hope, because I think previously you mentioned the situation in Russia and Ukraine right now. I was just wondering what about for the rest of Europe. Do you see any changes in consumer demand or just right now we are facing more of a logistical issue for these markets,

Yeah no, I think apart from Russia and Ukraine, we're actually seeing a very healthy growth for the Western European markets. So needless to say, that we are already market leader in countries like Italy and Spain, we are actually expanding very fast in countries like Eastern Europe for example, Poland, Czech Republic, as well as in the very strong foothold of Western Europe like Germany, UK, [Indiscernible], Nordics, we still think that there's going to be a lot of potential in Europe for us to grow because we have different product offerings and we have many exciting product offerings which are targeting more at sports and outdoor activities, which we're going to launch very soon. So hopefully with this new mix of new product introductions, we're able to grow our European market even bigger than what it is now.

Right. Thank you, very clear. Thank you.

The next question is from Clive Chong of Credit Suisse, please go ahead.

I thank your management for taking my question. My first question is on Xiaomi. Obviously, we continue to see the downtrend there in terms of Xiaomi product shipments. Trying to get a sense of management view on -- specifically on kind of the risks there and products. Do you see the end of the cycle or do you think it is just extension of the replacement cycle that is driving the slowdown of this shipments. And the second part to that question is with our discussion, with Xiaomi on the new products, could we get a sense, is that going to be a volume driver that could bring us back to previous -- shipment levers of previous years or is just a variation of kind of current product types and extending the product type a little bit longer? Thank you. That's my first question.

Okay. First, let me just comment on the Xiaomi relationship. You know that we actually sign the Xiaomi contract every three years. And then last year, we just renewed the new three-year period. So the relationship with Xiaomi is very strong. And we actually also have different co-operations with Xiaomi beyond the band and the different algorithms which we're working with them, right. So Xiaomi stays as a big shareholder of us and we have a lot of co-operations with Xiaomi. So that's the first thing I can guarantee you. On the Xiaomi new products, I think I touched this point. If you read the announcements which Xiaomi also published yesterday on the name change for that life, we also mentioned that we're going to explore more into the chips for the wearable, as well as the use of different algorithms and as well as the new form factor of products. And here forgive me, I cannot say too much, but definitely we want to actually drive the Xiaomi sales and continue with this relationship much further than what it is now. That's on Xiaomi and coming back on the Mi Band and the overall band market decline, I think, yes. I have mentioned that a few quarters already. We see overall band market as the form factor. That the market has been in decline for a few quarters already. And then yes, maybe it's coming to [Indiscernible] and it is going to be flat all over it. That's what we hoped for. But I think you are more looking at flatten out or slide slightly declined type of situation for the Band market. But at the same time, I felt what we mentioned in the earnings release as well on the specific Band market and market share for Xiaomi band. We stay still at 35%, which is by far crushing every other competitor, right? So I hope this would give you a feeling for what it is.

Yes, it does. Thank you very much. And my second question is on the R&D. Obviously, you have turned it down a little bit as a percentage of revenue. And I would just like to ask is -- do you think the kind of toning down was because it was elevated in prior years or -- and in fact, does that -- obviously, one of key advantages or key competitive advantages is in your research in developing those healthcare chipsets, and does this impact going forward or kind of research levels. Thank you.

I think I think yes, R&D has this -- is very much linked into the new product introduction as well, right? And different years we have different cadence, when we released our new products, for example, Q3 2020 was a very new product introduction rich type of quarter, than our R&D expenses in that quarter was extremely high. But seems we didn't have too much of new product launch in Q4, you have that GT3 was the only one which we pushed out in Q4 2021. So that's why also R&D expenses by nature, is also relatively lower compared with the same period last year. But on the other hand, we also asked the team to do and look at the return on investment on R&D developments. So instead of doing everything, and then in the end it becomes a waste, we are more prioritizing our R&D activities and using modernization, the mega plus type of approach to do the R&D activities more effectively. So, that also is one of the main levers whereby we can actually keep our competitive advantage while at the same time keeping the cost under control. But then if you actually pull a line on R&D expenses as a percentage of sales for the overall company, I think we stay as R&D driven company because the R&D expenses as a percentage of sales for the whole year, if you divided that by our sales, it's actually by far the highest among the selling expenses and G&A expenses. So, we're still spending roughly around 8% to 9% of the sales on R&D activities, although it's going to be up and down in different quarters. But if you pull it a line, I think we still have that [indiscernible 00:46:16] versus the other companies.

Okay. Thank you very much. I actually just have one question on the COVID impact. I was wondering if there has been some more forward-looking on fourth-quarter related, in the first quarter or in the recent week, had there been any impact to our manufacturing capacity given that?

Yes. No of course you're very sharp on this. Now so COVID actually posed a lot of uncertainties and negatively impacted all our results, right? In Q4, the sudden lock-down in a lot of European countries around the holiday seasons, actually dampened ourselves in the offline channels, right? So that also plays into why our numbers in Q4 was weaker than what we originally anticipated, right? And on the other hand, COVID, also create a lot of logistics nightmare for our supply chain. Talk for example, a especially and that's also one of the reasons why we guide the Q1 sales number, in a very conservative way, right? Because, as all the other Chinese company, our export route is actually through Shenzhen into Hong Kong. And then from Hong Kong goes to everywhere in the world, right? And then with the sudden lock down in Shenzhen and all the logistics flow also stopped. That actually post a lot of logistic challenge and supply chain nightmares to our team, so that's why we kind of guided a relatively lower number on our guidance for Q1. So yes, COVID definitely has an impact in the past, it was more on the overseas market. And now, if I look at Q1 and Q2, the zero - COVID policy in China definitely actually disrupted the supply chain and the manufacturing a little bit for us. But then as I said, also our supply chain team is looking for other different ways to resolve this situation. But that obviously takes time and would have played into some more conservativeness in our guidance going forward. But we think this situation should be much better as we entered the second half of this year.

Thank you very much. Very clear. Thank you.

The next question is from Andre Lin of Citi. Please go ahead.

Thank you for taking my question. And I have a follow-up question on the previous supply chain-related questions. And you mentioned there's a semiconductor supply challenge. So can you give us a color on how the situation is going and when do you expect the semiconductor supply challenge will all be resolved this year or next year?

I think I have mentioned that in the script earlier. We think going into the second half of 2022, the situation should be resolved or much better than what it is right now. I -- Q4 was very serious. And then we did certain risk buys and we did certain commitments, we're putting a lot of chips. And that's after a month or two, I think Q1, on certain product types, we don't have a shortage issue. But then on the other hand, you will see that also more semiconductor companies are prioritizing their chips towards the EV players. So that will have certain impact into Q2 as well. So we're more constrained by the supply rather than by the demand situation. But base out the current information I have on hand, it looks like by end of Q2, so from May onwards, this situation should be reserved to a much extent.

Thank you. That's [Indiscernible]. And I have a follow-up question is regarding the first quarter guidance. Can you give us a bit more color on the shipment or revenue guidance for the sales [Indiscernible] on top of the [Indiscernible] UK?

No, so this -- no, we are hurt by a lot of uncertainties in Q1, so it's really a difficult quarter. That's why we guided in a very conservative way. I think you also see a lot of companies because of this, they even stop giving the guidance. But okay, we're still trying to give a range although this range is a much wider range. There are a few issues. Number one is what I mentioned before, the lockdown of Shenzhen for the upcoming seven days, and if that seven days is going to continue into a 14 or 21 days. Nobody knows. But because of that lockdown, manufacturing stopped, logistics stopped. You cannot even export the products into Hong Kong. We're looking at other ways. For example, going through Tianjin to exports the products out of China, etc. But that would not -- would definitely have a negative impact in the initial outlook we have on Q1. And actually, the last two weeks in the quarter have always been one of the biggest moments of shipping for us because Q1 has been always a slow quarter, but then towards the end of Q1, the production and shipment start to pickup, that's actually placed into the relatively conservative outlook for which we issued. Number 2, is the Ukraine and Russia situation, as I mentioned that Ukraine and Russia place around 4% of our overall sales, so if your average it out I think every quarter, depends on the quarter, is talking about 80 million to 100 million of sales, right? And luckily we have the first month out and the second, the February sales were kind of somewhere cutting into the husks, so we actually lost the 1.5 months because of ruble depreciation and everything else. So, you need to actually, apple-to-apple comparison, strip out the impact on the sudden Russia and Ukraine situation, although at the same moment we're trying to look into different ways, in whether or not we can continue to sell into Russia. I think the third one, it's the ship shortage, as I just mentioned and explained many times. So these three factors kind of played into the number which we put out here. If the Shenzhen lock-down will be only seven days or even within the seven days we can continue to manage to export and the shipment, I think we'll probably end up more towards the high-end of the guidance range. But if not, I think we're probably just in the middle. That's so much color I can give you.

Thank you. That's very clear. Thank you very much. I have no more questions.

As there are no further questions now, I'd like to turn the call back over to the company for closing remarks.

Thank you. Once again for joining us today. If you have further questions, please feel free to contact the Investor Relations department through the contact information provided on our website or the Pearson group, the company's Investor Relations consult. Thank you.

This concludes the conference call. You may now disconnect your line. Thank you.